Truist Securities Initiates Coverage On Maze Therapeutics with Buy Rating, Announces Price Target of $68

Truist Securities has initiated coverage on Maze Therapeutics (NASDAQ: MAZE) with a Buy rating. The firm has set a price target of $68 for the stock.